LYRA Key Statistics, Chart & Performance
The current stock price of LYRA is 1.74 USD. In the past month the price decreased by -51.4%. In the past year, price decreased by -80.96%.
LYRA Technical Analysis
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LYRA. LYRA may be in some trouble as it scores bad on both profitability and health.
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -22.89. The EPS increased by 69.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LYRA Forecast & Estimates
9 analysts have analysed LYRA and the average price target is 23.46 USD. This implies a price increase of 1248.28% is expected in the next year compared to the current price of 1.74.
For the next year, analysts expect an EPS growth of 63.39% and a revenue growth -57.6% for LYRA
LYRA Ownership
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 30
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What does LYRA do?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Can you provide the latest stock price for LYRA THERAPEUTICS INC?
The current stock price of LYRA is 1.74 USD. The price decreased by -15.12% in the last trading session.
Does LYRA THERAPEUTICS INC pay dividends?
LYRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of LYRA stock?
LYRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting LYRA stock to perform?
9 analysts have analysed LYRA and the average price target is 23.46 USD. This implies a price increase of 1248.28% is expected in the next year compared to the current price of 1.74.
What is the Price/Earnings (PE) ratio of LYRA THERAPEUTICS INC (LYRA)?
LYRA THERAPEUTICS INC (LYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.89).
Is LYRA THERAPEUTICS INC (LYRA) expected to grow?
The Revenue of LYRA THERAPEUTICS INC (LYRA) is expected to decline by -57.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.